Supplementary Figures 1 - 5 from Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization

Authors:
  • BLBohua Li
    Bohua Li
  • YMYanchun Meng
    Yanchun Meng
  • LZLei Zheng
    Lei Zheng
  • XZXunmin Zhang
    Xunmin Zhang
  • QTQing Tong
    Qing Tong
  • WTWenlong Tan
    Wenlong Tan
  • SHShi Hu
    Shi Hu
  • HLHui Li
    Hui Li
  • YCYang Chen
    Yang Chen
  • JSJinjing Song
    Jinjing Song
  • GZGe Zhang
    Ge Zhang
  • LZLei Zhao
    Lei Zhao

Abstract
PDF file - 362K, Competitive binding assay (S1); TPL inhibits ErbB2 signaling in breast cancer cell lines (S2); ErbB2 knockdown inhibits ErbB2 signaling and results in growth inhibition in the MDA-MB-231 cell line (S3); TPL inhibited MDA-MB-231 breast cancer cell growth in a dose-dependent manner both in vitro and in vivo (S4); The effects of siRNA knockdown of EGFR or ErbB3 on the BT-474TraR cell line (S5).